Aura Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AURA research report →
Range $17 – $18
Price Chart
About the company
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology.
- CEO
- Natalie C. Holles
- IPO
- 2021
- Employees
- 113
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $632.51M
- P/E
- -3.44
- Fwd P/E
- 200.16
- PEG
- -0.36
- P/S
- 0.00
- P/B
- 1.84
- EV/EBITDA
- -4.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -73.18%
- ROIC
- -41.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-112,791,000
- Net Income
- $-106,191,000-22.2%
- EPS
- $-1.76-0.6%
- OCF Growth
- -6.2%
- FCF Growth
- -5.1%
- 52W High
- $9.54
- 52W Low
- $4.73
- 50D MA
- $7.12
- 200D MA
- $6.64
- Beta
- 0.40
- RSI (14)
- 37
- Avg Volume
- 751.28K
No earnings-call transcripts are available for AURA yet.
- Free Float
- 62.4%
- Shares Outstanding
- 103.44M
- Float Shares
- 64.51M
of shares held by institutions
127 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tcg Crossover Management, LLC | 9.53M | ▲ 9.53M |
| Suvretta Capital Management, LLC | 7.21M | ▲ 2.83M |
| Frazier Life Sciences Management, L.P. | 7.10M | ▲ 2.00M |
| Matrix Capital Management Company, LP | 6.92M | 0 |
| Long Focus Capital Management, LLC | 5.12M | ▲ 500.00K |
| Blackrock, Inc. | 4.71M | ▲ 1.12M |
| Adage Capital Partners Gp, L.L.C. | 4.64M | ▼ 241.13K |
| Caligan Partners LP | 4.30M | ▲ 4.07M |
| Vanguard Capital Management LLC | 4.10M | ▲ 1.86M |
| Fcpm Iii Services B.V. | 4.05M | ▲ 4.05M |
| Orbimed Advisors LLC | 3.33M | ▲ 3.33M |
| Medicxi Ventures Management (Jersey) Ltd | 3.04M | 0 |
Held by 145 ETFs
Biggest fund positions in AURA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Person Julie | other | 212,389 |
| Sep 1, 26 | Person Julie | other | 107,611 |
| Sep 1, 26 | Kratz Erica | other | 199,115 |
| Sep 1, 26 | Kratz Erica | other | 100,885 |
| Sep 1, 26 | Hopkins Janet Jill | other | 58,850 |
| Sep 1, 26 | Hopkins Janet Jill | other | 116,150 |
| Sep 1, 26 | Elazzouzi Amy | other | 23,540 |
| Sep 1, 26 | Elazzouzi Amy | other | 46,460 |
| Sep 1, 26 | Abu-Absi Susan | other | 265,487 |
| Sep 1, 26 | Abu-Absi Susan | other | 134,513 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AURA coverage
Recent articles, reports, and earnings notes.
No research on AURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AURA report →Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
defenseworld.net · Sep 7
Aura Biosciences to Participate in Upcoming Investor Conference
globenewswire.com · Sep 2
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA
defenseworld.net · Sep 2
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 1
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA
defenseworld.net · Aug 26
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
seekingalpha.com · Aug 12
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
globenewswire.com · Jul 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.